key: cord-0275116-r0q8ibo0
authors: Richardson, S. I.; Manamela, N. P.; Motsoeneng, B. M.; Kaldine, H.; Ayres, F.; Makhado, Z.; Mennen, M.; Skelem, S.; Williams, N.; Sullivan, N. J.; Misasi, J.; Gray, G. G.; Bekker, L.-G.; Ueckermann, V.; Rossouw, T.; Boswell, M. T.; Ntusi, N. A. B.; Burgers, W. A.; Moore, P. L.
title: A SARS-CoV-2 variant of concern triggers Fc effector function with increased cross-reactivity
date: 2021-11-05
journal: nan
DOI: 10.1101/2021.11.05.21265853
sha: f8d8b6efe1c37ece9355f9902d51de6397eb8508
doc_id: 275116
cord_uid: r0q8ibo0

SARS-CoV-2 variants of concern (VOCs) exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. However, while non-neutralizing cytotoxic functions of antibodies are associated with decreased disease severity and vaccine protection, Fc effector function escape from VOCs is poorly defined. Furthermore, whether VOCs trigger Fc functions with altered specificity, as has been reported for neutralization, is unknown. Here, we demonstrate that the Beta VOC partially evades Fc effector activity in individuals infected with the original (D614G) variant. However, not all functions are equivalently affected, suggesting differential targeting by antibodies mediating distinct Fc functions. Furthermore, Beta infection triggered responses with significantly improved Fc cross-reactivity against global VOCs compared to either D614G infected or Ad26.COV2.S vaccinated individuals. This suggests that, as for neutralization, the infecting spike sequence impacts Fc effector function. These data have important implications for vaccine strategies that incorporate VOCs, suggesting these may induce broader Fc effector responses.

Continued SARS-CoV-2 transmission worldwide in the absence of adequate vaccine coverage has resulted in the emergence of several viral variants of concern (VOCs)

including Alpha (B.1.1.7), Beta (B.1.351/501Y.V2), Gamma (P.1) and Delta (B.1.617.2).

These VOCs are generally able to evade neutralizing responses, with Beta, first identified in South Africa in October 2020 1 , showing the greatest capacity for neutralization escape from convalescent and vaccinee sera [2] [3] [4] [5] [6] . In contrast, preservation of T cell function and spike binding antibody levels has been described for several VOCs after both infection and vaccination 4, [7] [8] [9] . In addition to mediating neutralization, antibodies drive several effector functions through their ability to engage cellular receptors via their Fc portion, including antibody-dependent cellular cytotoxicity (ADCC), cellular phagocytosis (ADCP), cellular trogocytosis (ADCT) or cell membrane nibbling and complement deposition (ADCD).

Therefore, the presence of cross-reactive binding antibodies is consistent with reports of preserved Fc effector function in convalescent sera and after vaccination, and with effectiveness data showing that several vaccines maintain effectiveness against VOCs 2,7,10 .

For example, the Ad26.COV.2S vaccine maintained efficacy against severe COVID-19 illness as Beta emerged in South Africa despite substantially reduced neutralization titers 2, 4, 5, 11 .

The majority of antibodies elicited in response to infection are non-neutralizing 12 . As mutations in VOCs occur primarily in the RBD and the N-terminal domains targeted by neutralizing antibodies, antibodies able to bind outside of these sites and mediate potent antiviral function may be crucial for protection from severe infection. As for many other diseases, Fc effector function has been associated with reduced COVID-19 severity and mortality, suggesting an important early role for these functions in disease outcomes 13, 14 .

Furthermore, isolated antibodies from convalescent donors require Fc function for optimal . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 4 protection and therapeutic efficacy 15, 16 . Fc functions have also been shown to persist beyond neutralizing responses following SARS-CoV-2 infection, suggesting that these may be an important target for vaccine design 17, 18 .

Fc effector function correlated with protection through vaccination in non-human primates 10, 19, 20 and is potently elicited by vaccination in humans 2, 7, 21, 22 . Beyond this, nuances in the magnitude and breadth of Fc receptor binding responses from convalescent donors and different vaccine regimens suggests that these responses vary in response to stimulation by specific antigens, formulations or doses 23 .

For neutralization, there is strong evidence that the sequence of the infecting virus impacts the breadth of the resulting neutralizing antibodies 3, 9, 24 . Neutralizing antibodies triggered by VOCs show varying patterns of breadth compared to the original D614G and one another, suggesting that spikes with different genotypes differentially impact the repertoire of antibodies that they triggered. However, similar studies characterizing Fc effector functions in individuals infected with variants of concern have not yet been conducted. Since March 2020, South Africa has experienced three distinct waves of COVID-19 infection, each dominated by a different variant. In this study we leveraged these virologically distinct waves to define both Fc effector response escape from VOCs, and to describe Fc responses to VOCs. We used convalescent sera from individuals infected with Wuhan D614G to show that Beta partially evades several Fc effector functions. However, individuals infected with Beta developed Fc effector function with improved cross reactivity for all VOCs. Lastly, we show that Fc effector function elicited by the Ad26.COV.2.S vaccine is largely retained across VOCs, but is not as cross-reactive as those elicited by Beta. These findings illustrate that VOCs differentially trigger Fc effector functions, with important implications for vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint Binding antibodies, unlike neutralizing antibodies, retain high level activity against heterologous variants South Africa's first wave peaked in mid-July 2020, the second in January 2021 and the third in August 2021 ( Figure 1A ). The first wave was dominated by original Wuhan D614G, the second wave was driven by the Beta variant, and the third wave was almost exclusively Delta. We made use of convalescent plasma from the first two waves (first wave n = 27; second wave n = 21) to determine its ability to bind and neutralize the original (D614G) or Beta lineages. The first and second wave participants were hospitalized patients, who were closely matched in age with a median of 52 years (range 27-72) and 55 years (range 24-73), respectively. Samples were collected a median of 10 days (range 7-33) and 13 days (range 2-29) after a positive SARS-CoV-2 PCR test (Table S1 ). Although wave 1 viral sequences were not obtained, these samples were collected several months prior to the emergence of Beta in South Africa and were therefore assumed to have been infections caused by the original D614G lineage ( Figure 1A ). Wave 2 samples were collected when Beta accounted for >90% of infections in the region, with sequences from nasal swabs of 8/21 patients confirmed as Beta (Table S1) , as described previously 24 .

Comparison of the binding of IgA and IgG from Wave 1 plasma to the original (D614G) or Beta spikes showed a significant decrease in binding to Beta ( Figure 1B and C). In contrast, wave 2 plasma from Beta infections showed a significant increase in both IgA and IgG binding to Beta. However, the differences in geometric mean titer against the original and Beta spike for wave 1 and 2 plasma were less than 2-fold for both IgG and IgA. In contrast, neutralization titers in plasma from wave 1 decreased 14.7 fold against Beta, while wave 2 titers of Beta were 5.1 fold higher than those of D614G ( Figure 1C ). This is in line with our previous studies using samples from the same cohorts 6, 24 . This difference in reduction of binding and neutralizing antibodies confirms the ability of convalescent plasma to target epitopes beyond the neutralizing epitopes mutated in VOCs.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 6 Cross-reactivity of Fc effector function is differentially impacted by the sequence of the infecting spike We next measured whether Fc effector functions elicited in response to the original D614G variant or the Beta variant were equivalent in terms of magnitude and cross-reactivity. We measured spike-specific Fc responses using either spike protein coated on to fluorescent beads (for ADCP and ADCD) or spike expressed on the surface of target cells (ADCC and ADCT). In order to validate these assays, we tested the Fc effector function of monoclonal antibodies previously characterized for cell surface spike binding to D614G and Beta 25 .

A23-58.1, B1-182.1, A19-46.1 and A19-61.1 have previously been shown to bind D614G and Beta to similar levels, and therefore showed similar ADCP, ADCC, ADCD and ADCT activity against both D614G and Beta ( Figure S1 ). Similarly, Class 4 mAb CR3022, which binds to regions of the RBD that exclude sites mutated in Beta 26 , showed similar Fc effector function for both variants indicating that these assays were comparable across variants. For Class 2 mAbs BD23, LY-CoV555 and P2B-2F6, which are unable to bind or neutralize Beta 6, 27 , Fc effector function against Beta was similarly reduced.

Plasma from wave 1 participants all showed a significantly decreased ability to mediate ADCP, ADCC, ADCD and ADCT of Beta, compared to the original D614G spike, though all retained some activity against Beta ( is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint differences close to 1 for wave 2 samples (0.8, 0.9 and 1.1 for ADCP, ADCD and ADCT respectively) (Figure 2A and 2B).

As Fc effector function is modulated through Fc receptor binding, we examined the ability of antibodies from both wave 1 and 2 to crosslink dimeric Fcγ receptors FcγRIIa or FcγRIIIa (which modulate ADCP and ADCC activity, respectively) and the original or Beta spike protein by ELISA. As expected, Spearman's correlations exceeding 0.5 were noted between FcγRIIa binding and ADCP score, and between FcγRIIIa binding and ADCC against original D614G spike ( Figure S2A and B). Similar to the functional readout, wave 1 samples showed significant decreases in their ability to mediate Beta specific FcγRIIa ( Figure S2C ) and

FcγRIIIa cross-linking ( Figure S2D ), while no significant differences were noted for wave 2 samples ( Figure S2E ).

We considered the possibility that differences in Fc effector function simply reflected varying IgG levels between the waves, although the samples had been matched for age, severity and time since PCR test. Wave 1 and wave 2 samples showed no significant difference in IgG binding titers and ADCT activity to autologous spike ( Figure 1C and 2A; Figure S2F ). However, the wave 2 plasma showed significantly lower neutralization, ADCP and ADCC activity and enhanced ability to deposit complement protein compared to wave 1 plasma against autologous spike ( Figure S2F ). This illustrates that Fc effector VOC cross-reactivity is not as a result of binding titer. Overall, preserved Fc effector function, but substantial loss in neutralization against Beta in wave 1 samples ( Figure 2B ) suggests targeting by Fc effector function is distinct from that of neutralization.

Although Fc effector function elicited by the original D614G virus was not completely abrogated in response to Beta, the significant decrease in activity suggests that NTD and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint RBD, which are mutated in Beta, are substantial targets. Given the significant decrease of ADCC observed against Beta by wave 1 plasma (Figure 2A ) we sought to map these responses. Specifically, we determined the relative contribution to ADCC of antibodies targeting NTD and RBD by measuring FcγRIIIa signaling as a result of crosslinking to NTD or RBD proteins from the D614G and Beta variants.

First, we confirmed the ability of our assay to map these responses through the use of monoclonal antibodies. As for full spike ( Figure S1 ), CR3022 ADCC against the RBD was unaffected by mutations in the Beta RBD (K417N, E484K and N501Y) while ADCC mediated by P2B-2F6 was abrogated ( Figure 3A ). 4A8, an NTD targeted mAb for which neutralization and binding is escaped by Beta (L18F, D80A, D215G and 242-244 del) 6 showed ADCC activity against the original variant but not Beta RBD ( Figure 3B ).

ADCC mediated by wave 1 plasma showed a 2.2 fold decrease against Beta RBD (Median 663 and 308 for original and Beta respectively) confirming that while K417, E484 and N501 sites are targeted, they do not account for the majority of ADCC activity against the RBD ( Figure 3C ). Beta-elicited ADCC did not show significant differences between the original or Beta RBD ( Figure 3C ), which may suggest broader tolerance of RBD mutations in wave 2 plasma, consistent with neutralization. Similarly, ADCC was detected against the original NTD protein with a 3 fold decrease (median 677 to 204) against Beta in Wave 1 plasma ( Figure 3C ). This may indicate that ADCC antibodies more frequently target NTD sites mutated in Beta (L18, D80, D215), or are less able to tolerate the conformation change of the NTD that may result from the 242-244 deletion. Conversely, as for RBD, ADCC elicited by Beta was not significantly different against the original or Beta NTD ( Figure 3C ). Overall these data show that NTD and RBD are targets of ADCC responses in convalescent plasma. However, mutations in these key regions that allow for complete neutralization escape in individuals infected with the original (D614G) variant, only slightly affect ADCC.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint

of concern compared to wave 1 infection and Ad26.COV2.S vaccination As Beta-elicited plasma showed enhanced cross-reactivity for the original variants, we assessed a larger panel of global VOCs using cells expressing spikes from the original . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 1 0 Gamma 1.1; Delta 1). While responses against SARS-1 were significantly lower than most VOCs, they were detectable in some participants.

Vaccine and wave 1 ADCC against VOCs were similar, indicating comparable levels of cross reactivity ( Figure 4D ). Strikingly though, vaccine-elicited plasma showed decreased capacity to perform ADCC against Beta compared to wave 1 plasma ( Figure 4D ). For Beta, Gamma and Delta, the fold differences for wave 2 sera were consistently >1, and significantly different from wave 1 and Ad26.COV2.S, while Alpha and SARS-1 showed no difference ( Figure 4D ). This indicates that overall, Beta-elicited ADCC showed greater crossreactivity to global VOCs compared to original elicited ADCC by either vaccination or infection.

The emergence of variants that can escape neutralizing responses has compromised vaccine protection from infection, but in many cases not from severe disease. Several studies now support the notion that unlike neutralization, Fc effector function is more resilient in the face of VOCs 7, 23 . In this study we showed preservation of Fc effector function . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 .

While Fc effector functions against Beta were only slightly lower, loss of activity was not equivalent for all functions, with ADCD being most affected. RBD is a major target for complement binding in both vaccinated and convalescent individuals 28 , which may explain why this function in particular has greater loss against Beta, which has key immune evasion mutations in the RBD. In contrast to ADCD, ADCC activity against Beta was less reduced..

Our epitope mapping data indicates that Beta RBD and NTD are not the predominant targets of this function. Therefore preservation of ADCC may be the result of antibodies targeting epitopes or sites beyond those commonly mutated in VOCs. Differential epitope targeting has also been suggested for other functions, with RBD depletion greatly decreasing ADNP activity in contrast to ADCP, which remained unaffected in convalescent plasma 23 . In addition to antibody targeting that varied by function, we also show that individuals infected by different variants have unique Fc effector profiles despite similar levels of binding antibodies. These data suggest differential targeting of individual Fc functions in response to VOC. Further delineation of the targets of these responses may allow manipulation of future immunogens to specifically improve Fc effector functions.

We also show subtle differences in the ability of antibodies elicited by either the original D614G or the Ad26.COV2.S vaccine to perform ADCC against Beta. This was despite the fact that the sequence of immunodominant regions of the eliciting immunogens were the same, with only the single D614G mutation differing between them. Similar findings have been reported for ADCP, where RBD is targeted to varying levels in different vaccine . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. comparisons. *p<0.05; ***p<0.001; ****p<0.0001 and ns = non-significant.

First wave plasma samples (n = 27) were collected from participants enrolled to the Pretoria COVID-19 study cohort. Participants were admitted to Steve Biko Academic Hospital (Pretoria, South Africa) with moderate to severe (WHO scale 4-6) PCR confirmed SARS-CoV-2 infection between May and September 2020 ( Figure 1A ; 

Human embryo kidney HEK293T cells were cultured at 37°C, 5% CO2, in DMEM containing 

For wave 2 samples, sequencing of the spike was performed as previously described 24 using swabs obtained from 28 randomly collected Groote Schuur Hospital patients of which eight were included in this study. RNA sequencing was performed as previously published 1 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. incubating for six days at 37 °C, 70% humidity and 10% CO 2 , proteins were first purified using a nickel resin followed by size-exclusion chromatography. Relevant fractions were collected and frozen at -80 °C until use.

Two μ g/ml of spike protein (Original or Beta) was used to coat 96-well, high-binding plates and incubated overnight at 4 °C. The plates were incubated in a blocking buffer consisting of 5% skimmed milk powder, 0.05% Tween 20, 1x PBS. Plasma samples were diluted to 1:100 starting dilution in a blocking buffer and added to the plates. IgG or IgA secondary antibody was diluted to 1:3000 or 1:1000 respectively in blocking buffer and added to the plates followed by TMB substrate (Thermofisher Scientific). Upon stopping the reaction with 1 M H 2 SO 4 , absorbance was measured at a 450nm wavelength. In all instances, mAbs CR3022 and BD23 were used as positive controls and Palivizumab was used as a negative control.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 1 9

The SARS-CoV-2 Wuhan-1 spike, cloned into pCDNA3.1 was mutated using the 

For the neutralization assay, plasma samples were heat-inactivated and clarified by centrifugation. Heat-inactivated plasma samples from vaccine recipients were incubated with the SARS-CoV-2 pseudotyped virus for 1 hour at 37°C, 5% CO2. Subsequently, 1x10 4 HEK293T cells engineered to over-express ACE-2 (293T/ACE2.MF)(kindly provided by M.

Farzan (Scripps Research)) were added and incubated at 37°C, 5% CO 2 for 72 hours upon which the luminescence of the luciferase gene was measured. Titers were calculated as the reciprocal plasma dilution (ID50) causing 50% reduction of relative light units. CB6 and CA1

was used as a positive control.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 2 0

SARS-CoV-2 original or Beta spike was biotinylated using EZ link Sulfo-NHS-LC-Biotin kit (ThermoFisher) and coated on to fluorescent neutravidin beads as previously described 32 .

Briefly, beads were incubated for two hours with monoclonal antibodies at a starting concentration of 2 μ g/ml and titrated five-fold or plasma at a single 1 in 100 dilution. were normalised to each other and between runs using CR3022.

The ability of plasma antibodies to cross-link and signal through FcγRIIIa (CD16) and spike expressing cells or SARS-CoV-2 protein was measured as a proxy for ADCC. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. 

ADCD was measured as previously described 33 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 2 2 ADCT was performed as described in and modified from a previously described study 34 .

HEK293T cells transfected with a SARS-CoV-2 spike pcDNA vector as above were surface biotinylated with EZ-Link Sulfo-NHS-LC-Biotin as recommended by the manufacturer. Fiftythousand cells per well were incubated with 5-fold titration of mAb starting at 25 μ g/ml or single 1 in 100 dilution for 30 minutes. Following a RPMI media wash, these were then incubated with carboxyfluorescein succinimidyl ester (CFSE) stained THP-1 cells (5 X10 4 cells per well) for 1 hour and washed with 15mM EDTA/PBS followed by PBS. Cells were then stained for biotin using Streptavidin-PE and read on a FACSAria II. Trogocytosis score was determined as the proportion of CFSE positive THP-1 cells also positive for streptavidin-PE less the no antibody control.

High-binding 96 well ELISA plates were coated with 1 ug/ml spike protein in PBS overnight at 4°C. Three wells on each plate were directly coated with 5 ug/ml IgG, isolated from healthy donors, and signals from these wells were used to normalize the Fc receptor activity of the plasma samples. Plates were washed with PBS and blocked with PBS/1 mM EDTA/1% BSA for 1 hour at 37°C. Plates were then washed and incubated with 1:10 diluted plasma for 1 hour at 37°C and then with 0.2 ug/ml or 0.1 ug/ml of biotinylated FcγRIIa or FcγRIIIa dimer respectively (constructs kindly provided by Prof. Mark Hogarth from the Burnet Institute, Australia) for 1 hour at 37°C 35 . Subsequently, a 1:10,000 dilution of Pierce high-sensitivity streptavidin-horseradish peroxidase (Thermo Scientific) was added for a final incubation for 1 hour at 37°C. Lastly, TMB substrate (Sigma-Aldrich) was added, and color development was stopped with 1 M H 2 SO 4 and absorbance read at 450 nm.

Analyses were performed in Prism (v9; GraphPad Software Inc, San Diego, CA, USA). Nonparametric tests were used for all comparisons. The Mann-Whitney and Wilcoxon tests were used for unmatched and paired samples, respectively. The Friedman test with Dunns . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. titer, binding as EC50, ADCP as ADCP score, ADCC as FcγRIIIa signalling RLU, ADCD as MFI od C3 deposition and ADCT as ADCT score. Statistical differences between wave 1 and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint 2 4 2 were calculated by Mann Whitney t test where *p<0.05; ***p<0.001; ****p<0.0001 and ns = non-significant and bars indicate the median activity. 

Detection of a SARS-CoV-2 variant of concern in South Africa

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in . CC-BY-NC-ND 4.0 International license COVID-19 convalescent donors and vaccinees. Sci Immunol

Loss of recognition of SARS-CoV-2 B.1.351 variant spike epitopes but overall preservation of T cell immunity

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Targeting Fc effector function in vaccine design

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset

Decay of Fc-dependent antibody functions after mild to moderate COVID-19

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles

Reactive Neutralizing Antibody Responses Elicited by SARS-CoV

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection. medRxiv

Emergence and phenotypic characterization of C.1.2, a globally detected lineage that rapidly accumulated mutations of concern. medRxiv

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

We thank Dr Bronwen Lambson, Donald Mhlanga and Brent Oosthuysen for generating viral variants of concern. We thank Mashudu Madzivhandila and Thandeka Moyo-Gwete for . CC-BY-NC-ND 4.0 International license It is made available under a

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted November 5, 2021. ; https://doi.org/10.1101/2021.11.05.21265853 doi: medRxiv preprint